PDCD1 and hepatocellular carcinoma: However, the toxicities associated with anti-PD1 treatment at approved dose levels and HBV reactivation due to the residual viral genome may pose hurdles for its sole use as a prophylactic measure against HCC occurrence [39,40,41].